Aura Renew Acq Regulatory News (ARA)

13 Feb 2007 07:01

Ardana PLC13 February 2007 ARDANA SIGNS AGREEMENT WITH TWINPHARMA TO MARKET STRIANTTM SR IN THE NETHERLANDS Edinburgh, UK, 13 February 2007: Ardana plc (LSE:ARA) today announces that ithas signed an agreement granting TwinPharma BV ("TwinPharma") exclusive rightsto market StriantTM SR in the Netherlands. StriantTM SR is a mucoadhesive buccal (gum surface) testosterone replacementtherapy for confirmed male hypogonadism (i.e. those suffering from a deficiencyor absence of testosterone). StriantTM SR is the first-to-market buccal adhesivetablet and is marketed to urologists and endocrinologists by Ardana's own salesforce in the UK, and via partners in Germany, Ireland and the Nordic Region. TwinPharma will shortly launch StriantTM SR in the Netherlands as pricing andreimbursement has now been agreed with the Netherlands Health Authority. Dr. Maureen Lindsay, Chief Executive of Ardana, said: "Today's announcementshows Ardana's continued commitment to expand its product portfolio into theEuropean market with specialist collaborations in each country. We are verypleased to be working with TwinPharma to ensure that we continue to introducenovel therapies for indications where there are unmet patient needs." Gert van Alewijk and Bauke Buwalda, founders of TwinPharma, said: "We set upTwinPharma with the ambition to introduce novel medicines into the Dutch market.StriantTM SR is a truly novel therapy and fits perfectly with the strategic viewof TwinPharma. The collaboration with Ardana Bioscience is very professional andinspiring and we are looking forward to a successful and pleasant cooperation." For more information contact:Ardana Financial DynamicsMaureen Lindsay (corporate/financial media relations)Tel: + 44 (0) 131 226 8550 Julia Phillips/John Gilbert Tel: +44 (0)20 7831 3113TwinPharmaBauke BuwaldaTel: + 31 (0) 348 493015 About Ardana Ardana plc is a pharmaceutical company focused on the discovery, development andmarketing of innovative products to improve human reproductive health, a $25.5billion market. Since its foundation, Ardana has built a broad and balanced portfolio to managerisk and actively pursues product and technology in-licensing and outlicensingto maintain a robust pipeline. Ardana's lead products are summarised below: • Emselex(R), a once a day treatment for the symptoms of overactive bladder syndrome, which Ardana has exclusive UK marketing and promotion rights and is being distributed in collaboration with Novartis UK Limited; • StriantTM SR, a testosterone replacement therapy that has been launched by Ardana through its own sales force in the UK and through marketing partners in certain European countries, as a treatment for men with confirmed hypogonadism; • Teverelix LA, in development for three initial indications (prostate cancer, benign prostatic hyperplasia and endometriosis); • Testosterone Cream, a trans dermal testosterone delivery system in development for the treatment of male hypogonadism, in Phase II trials; • InvicorpTM, an injectable combination drug treatment for erectile dysfunction, for which Ardana has marketing and manufacturing rights in Europe and has been launched in Denmark. • EP01572 a growth hormone secretagogue in late stage development for the diagnosis of growth hormone deficiency In addition, Ardana has a strong portfolio of follow-on products in development. Ardana is listed on the Main Market of the London Stock Exchange. For further information please see www.ardana.co.uk This information is provided by RNS The company news service from the London Stock Exchange